CLBT Stock Analysis: Cellebrite DI | NASDAQ
Software - Infrastructure | NASDAQ, USA | Market Cap: 3.007m USD | 12M Return: -26.7% | IL0011794802 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 34.1M
EPS Trend: 87.6%
Qual. Beats: -1
Rev. Trend: 99.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cellebrite DI Ltd. (NASDAQ: CLBT) is an Israel-based software company specializing in digital forensics and investigative solutions for legally sanctioned cases. Its platform spans the full investigative lifecycle-access, collection, review, extraction, decryption, analysis, and management of digital evidence-serving law enforcement, government agencies, corporations, and service providers across Europe, the Middle East, Africa, the Americas, and Asia-Pacific. Use cases include child exploitation, homicide, anti-terror, border control, organized crime, human trafficking, corporate security, intellectual property theft, and financial crimes involving cryptocurrency.
The companys product suite includes Inseyets (digital forensics software), Guardian Forensics (evidence management), Guardian Collaborate (evidence sharing), Guardian Investigate (case management with AI-powered analytics), and Cellebrite Pathfinder for automated evidence review. Through its Corellium subsidiary, Cellebrite offers mobile vulnerability research and penetration testing tools (Falcon and Viper), and it complements its software with professional, training, and certification services. As a vendor of investigative analytics and digital evidence management software to public-sector and enterprise clients, Cellebrite operates in a niche segment of the broader application software and cybersecurity markets, with a business model built on enterprise/government software licensing, subscriptions, and associated services.
- Federal law enforcement spending boosts subscription revenue
- Subscription model shift expands gross margins and ARR
- Apple and Google encryption tighten mobile data extraction access
| Net Income: 58.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 25.83 > 1.0 |
| NWC/Revenue: 42.58% < 20% (prev 67.81%; Δ -25.22% < -1%) |
| CFO/TA 0.15 > 3% & CFO 153.0m > Net Income 58.8m |
| Net Debt (-419.3m) to EBITDA (113.6m): -3.69 < 3 |
| Current Ratio: 1.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (252.8m) vs 12m ago 1.53% < -2% |
| Gross Margin: 82.96% > 18% (prev 84.38%; Δ -1.42% > 0.5%) |
| Asset Turnover: 57.73% > 50% (prev 55.46%; Δ 2.27% > 0%) |
| Interest Coverage Ratio: 174.1 > 6 (EBIT TTM 91.1m / Interest Expense TTM 523k) |
| A: 0.22 (Total Current Assets 583.2m - Total Current Liabilities 364.2m) / Total Assets 994.3m |
| B: -0.07 (Retained Earnings -69.2m / Total Assets 994.3m) |
| C: 0.10 (EBIT TTM 91.1m / Avg Total Assets 890.9m) |
| D: 1.18 (Book Value of Equity 538.1m / Total Liabilities 456.2m) |
| Altman-Z'' = 3.14 = A |
| DSRI: 1.01 (Receivables 110.8m/93.1m, Revenue 514.3m/436.7m) |
| GMI: 1.02 (GM 84.38% / 82.96%) |
| AQI: 2.04 (AQ_t 0.37 / AQ_t-1 0.18) |
| SGI: 1.18 (Revenue 514.3m / 436.7m) |
| TATA: -0.09 (NI 58.8m - CFO 153.0m) / TA 994.3m) |
| Beneish M = -2.27 (Cap -4..+1) = BBB |
As of September 01, 2026, the stock is trading at USD 12.00 with a total of 1,330,070 shares traded. Over the past week, the price has changed by +4.44%, over one month by -18.64%, over three months by -24.39% and over the past year by -26.65%.
Current recommended Stop Loss: 10.70 (which is 10.8% or 1.6 ATR below the current price).
Cellebrite DI has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy CLBT.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.4 | 28% |
P/E Trailing = 52.1304
P/E Forward = 35.7143
P/S = 5.8468
P/B = 5.7256
Revenue TTM = 514.3m USD
EBIT TTM = 91.1m USD
EBITDA TTM = 113.6m USD
Long Term Debt = 17.5m USD (estimated: total debt 23.2m - short term 5.74m)
Short Term Debt = 5.74m USD (from shortTermDebt, last quarter)
Debt = 23.2m USD (from shortLongTermDebtTotal, last quarter) (leases 22.8m already included)
Net Debt = -419.3m USD (calculated: Debt 23.2m - CCE 442.5m)
Enterprise Value = 2.59b USD (3.01b + Debt 23.2m - CCE 442.5m)
Interest Coverage Ratio = 174.1 (Ebit TTM 91.1m / Interest Expense TTM 523k)
EV/FCF = 23.60x (Enterprise Value 2.59b / FCF TTM 109.6m)
FCF Yield = 4.24% (FCF TTM 109.6m / Enterprise Value 2.59b)
FCF Margin = 21.32% (FCF TTM 109.6m / Revenue TTM 514.3m)
Net Margin = 11.43% (Net Income TTM 58.8m / Revenue TTM 514.3m)
Gross Margin = 82.96% ((Revenue TTM 514.3m - Cost of Revenue TTM 87.6m) / Revenue TTM)
Gross Margin QoQ = 80.78% (prev 82.53%)
Tobins Q-Ratio = 2.60 (Enterprise Value 2.59b / Total Assets 994.3m)
Interest Expense / Debt = 2.25% (Interest Expense 523k / Debt 23.2m)
Taxrate = 22.05% (16.6m / 75.4m)
NOPAT = 71.0m (EBIT 91.1m * (1 - 22.05%))
Current Ratio = 1.53 (Total Current Assets 583.2m / Total Current Liabilities 382.3m)
Debt / Equity = 0.04 (Debt 23.2m / totalStockholderEquity, last quarter 538.1m)
Debt / EBITDA = -3.69 (Net Debt -419.3m / EBITDA 113.6m)
Debt / FCF = -3.82 (Net Debt -419.3m / FCF TTM 109.6m)
Total Stockholder Equity = 495.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.60% (Net Income 58.8m / Total Assets 994.3m)
RoE = 11.87% (Net Income TTM 58.8m / Total Stockholder Equity 495.2m)
RoCE = 17.77% (EBIT 91.1m / Capital Employed (Equity 495.2m + L.T.Debt 17.5m))
RoIC = 11.64% (NOPAT 71.0m / Invested Capital 610.1m)
WACC = 7.46% (E(3.01b)/V(3.03b) * Re(7.50%) + D(23.2m)/V(3.03b) * Rd(2.25%) * (1-Tc(0.22)))
Discount Rate = 7.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.56 | Cagr: 11.76%
[DCF] Terminal Value 75.44% ; FCFF base≈109.6m ; Y1≈110.1m ; Y5≈116.6m
[DCF] Fair Price = 8.90 (EV 1.81b - Net Debt -419.3m = Equity 2.23b / Shares 250.8m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 87.63 | EPS CAGR: 24.08% | SUE: -1.97 | # QB: -1
Revenue Correlation: 99.72 | Revenue CAGR: 20.55% | SUE: -0.35 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.16 | Chg30d=+0.38% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=0.55 | Chg30d=-1.06% | Revisions=+38% | GrowthEPS=+7.6% | GrowthRev=+17.0%
EPS next Year (2027-12-31): EPS=0.65 | Chg30d=-1.18% | Revisions=+62% | GrowthEPS=+19.1% | GrowthRev=+15.1%
[Analyst] Revisions Ratio: +47% (up=11, down=3)